scholarly journals Erectile Dysfunction and Its Management: An Update

2013 ◽  
Vol 23 (2) ◽  
pp. 5-17
Author(s):  
Abdus Saleque Mollah ◽  
Md Iftikher Hossain Khan
Keyword(s):  
Erectile Dysfunction ◽  
Oral Therapy ◽  
Neurological Diseases ◽  
Alternative Therapy ◽  
Chronic Illnesses ◽  
Fear Of Failure ◽  
Sexual Intimacy ◽  
First Line ◽  
Phosphodiesterase 5 ◽  
First Line Treatment

Erectile dysfunction (ED) defined as "the inability to achieve or maintain an erection sufficient for sexual intercourse”—is one of the most common sexual dysfunctions in men. Some men assume that erectile failure is a natural part of the aging process and tolerate it, for others it is devastating. Withdrawal from sexual intimacy because of fear of failure can damage relationships and have a profound effect on overall wellbeing for the couple. Erectile dysfunction often accompanies chronic illnesses, such as diabetes mellitus, heart disease, hypertension, and a variety of neurological diseases. Therefore, physicians need to identify any underlying co-existing organic diseases in their patients presenting with ED. Whenever possible, patients are encouraged to attend their consultation sessions with their partners because ED is a condition affecting the couple' and not just the man. Psychogenic aspects of ED should also be explored during the consultation. The first-line treatment of ED is oral phosphodiesterase-5 inhibitors. For those who do not respond to oral therapy, there is no defined 'step-ladder' escalation in alternative therapy. It is up to the physician to discuss the options with the patient or couple and reach a decision based on their preference. JCMCTA 2012 ; 23 (2): 5-17

Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine (nab-P+G) versus FOLFIRINOX (FFX) in first-line treatment of advanced pancreatic adenocarcinoma (PDAC) in a U.S. community oncology setting.

2016 ◽  
Vol 34 (4_suppl) ◽  
pp. 433-433 ◽  
Author(s):  
Fadi S. Braiteh ◽  
Manish Patel ◽  
Monika Parisi ◽  
Quanhong Ni ◽  
Si yeon Park ◽  
...  
Keyword(s):  
Supportive Care ◽  
Real World ◽  
Alternative Therapy ◽  
Line Treatment ◽  
First Line ◽  
Eligibility Criteria ◽  
Kaplan Meier ◽  
Community Oncology ◽  
Nationally Representative ◽  
First Line Treatment

433 Background: Both nab-P+G and FFX demonstrated superior overall survival (OS) over gemcitabine monotherapy for the treatment of PDAC; but there is no real-world effectiveness and utilization study of nab-P+G vs. FFX. The objective of this study is to compare real-world treatment patterns of patients receiving nab-P+G vs. FFX as first-line treatment for advanced PDAC. Methods: A retrospective cohort study was performed using fully de-identified data from a nationally representative electronic medical record platform of 1,300 community oncology physicians. Patients diagnosed with PDAC between September 2013 and October 2014 who received either nab-P+G or FFX as 1st line therapy were included in the analysis. We calculated median time to treatment discontinuation (TTD) and database persistence (DP), a proxy for OS, using the Kaplan Meier method, and assessed supportive care usage with Poisson regression. Results: 202 (out of 851) patients met eligibility criteria (nab-P+G, n = 122; FFX, n = 80). Patients on nab-P+G were older than patients on FFX (mean age 67.0 v 61.4; p < 0.01), but other baseline characteristics were comparable. TTD (3.4 v 3.8 mos) and DP (8.6 v 8.6 mos) were not statistically different for nab-P+G and FFX, respectively. The rate of AE-related discontinuation was similar in patients on nab-P+G and FFX (18% v 21%); however patients on nab-P+G utilized less doses of granulocyte-colony stimulating factor (GCSF) agents (2.0 v 4.4; p < 0.01), but needed more doses of erythropoietin-stimulating agents (ESA) (0.9 v 0.1; p < 0.01) and steroids (7.9 v 5.8; p < 0.01) per 100 days. Conclusions: TTD and DP for patients with advanced PDAC did not differ significantly between nab-P+G and FFX, although supportive care medications differed. Patients treated with nab-P+G required fewer doses of GCSF and more doses of ESA and steroids, though AEs leading to discontinuation was not statistically different. Management of chemotherapy related toxicities may incur substantial burden on the U.S. healthcare system, especially if an alternative therapy exists with similar clinical outcomes.

Effectiveness of Oral L-Arginine in First-Line Treatment of Erectile Dysfunction in a Controlled Crossover Study

1999 ◽  
Vol 63 (4) ◽  
pp. 220-223 ◽  
Author(s):  
T. Klotz ◽  
M.J. Mathers ◽  
M. Braun ◽  
W. Bloch ◽  
U. Engelmann
Keyword(s):  
Erectile Dysfunction ◽  
Crossover Study ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

Dr. Run Wang: penile implant as the first line treatment for severe erectile dysfunction

ASVIDE ◽  
2018 ◽  
Vol 5 ◽  
pp. 071-071
Author(s):  
Bella Poon ◽  
Mira Wu ◽  
Cora W. Xu ◽  
Silvia L. Zhou
Keyword(s):  
Erectile Dysfunction ◽  
Line Treatment ◽  
First Line ◽  
Severe Erectile Dysfunction ◽  
Penile Implant ◽  
First Line Treatment

Pharmacotherapy of Restless Legs Syndrome with Pramipexole

2010 ◽  
Vol 2 ◽  
pp. CMT.S3580
Author(s):  
Giovanni Merlino ◽  
Simone Lorenzut ◽  
Martina Sommaro ◽  
Gian Luigi Gigli ◽  
Mariarosaria Valente
Keyword(s):  
Sleep Disorder ◽  
Restless Legs Syndrome ◽  
Dopamine Agonists ◽  
High Selectivity ◽  
Neurological Diseases ◽  
Line Treatment ◽  
Subjective Symptoms ◽  
First Line ◽  
Restless Legs ◽  
First Line Treatment

Restless Legs Syndrome (RLS) is one of the most common neurological diseases characterized by an urge to move the legs, often associated with unpleasant sensations relieved by movement. It is engendered by rest, and is worse in the evening or at night. Patients affected by severe RLS should be treated pharmacologically. Dopamine-agonists represent the first-line treatment for RLS symptoms. Pramipexole is a non-ergot derived dopamine agonist with a high selectivity for D2 and D3 receptors. At doses comprised between 0.125 and 0.75 mg, pramipexole improves subjective symptoms and objective signs of primary RLS even after the first administration. In addition, pramipexole seems to be safe and well tolerated. However, physicians should be aware that augmentation and compulsive behaviours might occur in their RLS patients treated with pramipexole. Further studies are needed to confirm the efficacy of pramipexole in uremic RLS and in children affected by the sleep disorder.

Sign in / Sign up

Export Citation Format

Share Document